Top Ten most popular articles on Pharmafile.com this week!
pharmafile | February 8, 2019 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | FDA, GSK, Merck, Pfizer, falsified medicines, strike, top 10
The strike in Ireland featured twice in this week’s top 10 after Pfizer employees in County Cork lost a dispute over pensions. Two of our features also appeared in the top stories of the week. While ‘Counterfeit drugs – countering the lies’, picks apart ‘common sense’ claims on counterfeit drugs in asking to what extent the problem of falsified medicines is a problem at all; ‘Repurposed drugs’ looks at the Supreme Court ruling on the Lyrica patent and asks what it means.
However, the top story of this week covered GSK move to buy Merck of Darmstadt’s immunotherapy cancer treatment in a deal worth up to $4.2 billion. Check out this week’s top 10!
10. Mylan’s Wixela becomes first FDA-approved generic version of GSK’s Advair inhaler
Mylan’s Wixela has become the first generic version of GlaxoSmithKline’s Advair Diskus (fluticasone propionate and salmeterol inhalation powder) inhaler to be approved in the US.
9. Obesity-related cancers on the rise amongst millennials
Cancers related to obesity are on the rise in young adults, according to findings from the American Cancer Society, published in The Lancet Public Health.
8. HIV drug holds hope for Alzheimer’s after significantly reducing inflammation in mice
Lamivudine, a generic drug for HIV, significantly reduces age-related inflammation and other signs of aging in mice, according to a study published in Nature.
7. Lilly’s Olumiant impresses in twin Phase 3 atopic dermatitis trials
Eli Lilly has unveiled new Phase 3 data from two studies into the oral Janus kinase (JAK) inhibitor Olumiant (baricitinib). The company and its partner Incyte announced that the drug had met its primary endpoint as a monotherapy in the treatment of adult patients with moderate to severe atopic dermatitis (AD).
6. Pfizer ignores strike in Ireland as 900 employees’ pensions affected
US multinational Pfizer is going ahead with its decision to transfer 900 of its Irish employees into a new defined contribution pension plan on 1 April, the company has said.
5. Feature: Repurposed drugs: The Supreme Court deals a blow to patentees
Second medical use patents protect the discovery that an existing drug is effective to treat a new condition. But, following the Supreme Court ruling in the Lyrica (pregabalin) case, how are such patents infringed, and what does it mean as we enter 2019?
4. Takeda ordered to pay Bayer $155.19 million over patent infringement
A US court has ordered Takeda Pharmaceutical’s Baxalta unit to pay German firm Bayer AG $155.19 million for infringement of a patent related to Baxalta’s haemophilia treatment Adynovate.
3. 400 Pfizer employees set to strike over pensions
400 Pfizer employees are set to go on strike in Ireland over an ongoing pensions dispute.
2. Feature: Counterfeit drugs – countering the lies
As the Falsified Medicines Directive comes into effect in February 2019, Louis Goss fact checks ‘common sense’ claims on counterfeit drugs
1. GSK buys Merck KGaA’s cancer immunotherapy for $4.2 billion
British multinational GlaxoSmithKline has agreed to pay up to €3.7 billion ($4.2 billion) for the rights to Merck KGaA’s next generation cancer immunotherapy.
Related Content
GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis
GSK’s Exdensur (depemokimab), a twice-yearly biological medicine, has received approval from the UK Medicines and …
Rethinking oncology trial endpoints with generalised pairwise comparisons
For decades, oncology trials have been anchored to a familiar set of endpoints. Overall survival …
Alto Neuroscience’s schizophrenia treatment granted FDA Fast Track designation
Alto Neuroscience has announced that its investigational treatment for cognitive impairment associated with schizophrenia (CIAS) …
